Ivacaftor: Five-year outcomes in the West of Scotland cystic fibrosis population.

Introduction: Ivacaftor has shown to be effective in patients with cystic fibrosis (CF) with a G551D mutation.

Objectives: This work aims to evaluate ivacaftor's effectiveness and safety in the real world, over 5 years, in the West of Scotland CF population.

Methods: We evaluated ivacaftor's effect on pulmonary function, body mass index (BMI), hospital bed occupancy, and adverse effects in patients ≥6 years with at least one G551D mutation.